Bright Minds Biosciences (XCNQ:DRUG) Total Equity : C$6.03 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Total Equity?

Bright Minds Biosciences's total equity for the quarter that ended in Dec. 2023 was C$6.03 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bright Minds Biosciences Total Equity Historical Data

The historical data trend for Bright Minds Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Total Equity Chart

Bright Minds Biosciences Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Total Equity

0.73

19.40

10.54

6.60

Bright Minds Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Equity	Get a 7-Day Free Trial												10.97	8.95	7.73	6.60	6.03

Bright Minds Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bright Minds Biosciences's Total Equity for the fiscal year that ended in Sep. 2023 is calculated as

Total Equity	=	Total Assets(Q: Sep. 2023 )	-	Total Liabilities(Q: Sep. 2023 )
	=	6.879	-	0.281
	=	6.60

Bright Minds Biosciences's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	6.887	-	0.854
	=	6.03

Bright Minds Biosciences Total Equity Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bright Minds Biosciences (XCNQ:DRUG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

DRUG:USA

Address

19 Vestry Street, New York, NY, USA, 10013

Website

https://www.brightmindsbio.com

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Executives

Jeremy Fryzuk

Director